RedHill Biopharma (RDHL) Asset Writedowns and Impairment (2017 - 2022)
RedHill Biopharma has reported Asset Writedowns and Impairment over the past 4 years, most recently at $1.5 million for Q4 2022.
- Quarterly Asset Writedowns and Impairment fell 85.88% to $1.5 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2022, down 62.93% year-over-year, with the annual reading at $6.0 million for FY2022, 62.93% down from the prior year.
- Asset Writedowns and Impairment was $1.5 million for Q4 2022 at RedHill Biopharma, down from $1.6 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $10.7 million in Q4 2021 and troughed at $1.1 million in Q1 2020.
- The 3-year median for Asset Writedowns and Impairment is $1.8 million (2020), against an average of $2.4 million.
- Year-over-year, Asset Writedowns and Impairment surged 417.28% in 2021 and then crashed 85.88% in 2022.
- A 3-year view of Asset Writedowns and Impairment shows it stood at $2.1 million in 2020, then surged by 417.28% to $10.7 million in 2021, then crashed by 85.88% to $1.5 million in 2022.
- Per Business Quant, the three most recent readings for RDHL's Asset Writedowns and Impairment are $1.5 million (Q4 2022), $1.6 million (Q3 2022), and $1.3 million (Q2 2022).